60 patents
Utility
Co-stimulatory Domains for Use In Genetically-modified Cells
18 Jan 24
The present disclosure provides novel co-stimulatory domains useful in genetically-modified cells to promote cell proliferation and/or promote cytokine secretion after antigen recognition.
Derek Jantz, Aaron Martin, Daniel T. MacLeod
Filed: 21 Aug 23
Utility
Polynucleotides Encoding Engineered Meganucleases Having Specificity for Recognition Sequences In the Dystrophin Gene
18 Jan 24
The present disclosure encompasses engineered meganucleases that bind and cleave recognition sequences within a dystrophin gene.
Gary Owens, Janel Lape, James Jefferson Smith, John Morris, Caitlin Turner, Whitney Lewis, Derek Jantz
Filed: 27 Jul 23
Utility
Engineered Meganucleases Having Specificity for a Recognition Sequence In the Transthyretin Gene
11 Jan 24
The present invention encompasses engineered meganucleases that bind and cleave a recognition sequence within a TTR gene.
Cassandra Gorsuch, Jochen Genschel, Janel Lape, Derek Jantz, James Jefferson Smith
Filed: 20 Aug 21
Utility
Optimized Engineered Nucleases Having Specificity for the Human T Cell Receptor Alpha Constant Region Gene
4 Jan 24
The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within the first exon of the human T cell receptor (TCR) alpha constant region gene.
James Jefferson Smith, Janel Lape, Hui Li, Jochen Genschel
Filed: 5 Sep 23
Utility
Genetically-modified Cells Comprising a Modified Human T Cell Receptor Alpha Constant Region Gene
4 Jan 24
Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor.
Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
Filed: 17 Jan 23
Utility
Polynucleotides Encoding Engineered Meganucleases Having Specificity for Recognition Sequences In the Dystrophin Gene
4 Jan 24
The present disclosure encompasses engineered meganucleases that bind and cleave recognition sequences within a dystrophin gene.
Gary Owens, Janel Lape, James Jefferson Smith, John Morris, Caitlin Turner, Whitney Lewis, Derek Jantz
Filed: 27 Jul 23
Utility
Rationally-designed Single-chain Meganucleases with Non-palindromic Recognition Sequences
28 Dec 23
Disclosed are rationally-designed, non-naturally-occurring meganucleases in which a pair of enzyme subunits having specificity for different recognition sequence half-sites are joined into a single polypeptide to form a functional heterodimer with a non-palindromic recognition sequence.
James Jefferson Smith, Derek Jantz
Filed: 17 Mar 23
Utility
Lipid Nanoparticle Compositions
16 Nov 23
The present invention provides lipid nanoparticle compositions, and methods of using the same, that are useful for introducing nucleic acids into eukaryotic cells, such as human immune cells.
Tyler Goodwin
Filed: 6 Oct 21
Utility
Optimization of Engineered Meganucleases for Recognition Sequences
26 Oct 23
The invention provides engineered meganucleases, derived from I-Cre1, which have substitutions at particular positions that increase the activity of the nucleases for recognition sequences containing certain center sequences.
James Jefferson Smith, Hui Li
Filed: 11 Aug 22
Utility
Engineered Meganucleases That Target Human Mitochondrial Genomes
21 Sep 23
Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human mitochondrial DNA (mtDNA).
James Jefferson Smith, Ginger Tomberlin, John Morris, Wendy Shoop, Carlos T. Moraes
Filed: 30 Jan 23
Utility
Genetically-modified Immune Cells Comprising a Microrna-adapted Shrna (Shrnamir)
7 Sep 23
The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein.
Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
Filed: 17 Aug 22
Utility
Precise Deletion of Chromosomal Sequences In Vivo and Treatment of Nucleotide Repeat Expansion Disorders Using Engineered Nucleases
29 Jun 23
The present invention provides a method of treating a nucleotide repeat expansion disorder comprising delivering a pair of engineered nucleases, or genes encoding engineered nucleases, to the cells of a patient such that the two nucleases excise the nucleotide repeat responsible for the disease permanently from the genome.
James Jefferson Smith, Victor Bartsevich, Derek Jantz
Filed: 17 Jun 22
Utility
Recognition Sequences for I-crei-derived Meganucleases and Uses Thereof
23 Mar 23
Methods of cleaving double-stranded DNA that can be recognized and cleaved by a rationally-designed, I-CreI-derived meganuclease are provided.
Derek Jantz, James Jefferson Smith
Filed: 13 Jul 22
Utility
Engineered Meganucleases Having Specificity for Recognition Sequences In the Dystrophin Gene
16 Feb 23
The present disclosure encompasses engineered meganucleases that bind and cleave recognition sequences within a dystrophin gene.
Gary Owens, Janel Lape, James Jefferson Smith, John Morris, Caitlin Turner, Whitney Lewis, Derek Jantz
Filed: 13 Sep 22
Utility
Optimized Engineered Meganucleases Having Specificity for a Recognition Sequence In the Hepatitis B Virus Genome
2 Feb 23
The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within a Hepatitis B virus (HBV) genome.
Janel Lape, James Jefferson Smith
Filed: 4 Dec 20
Utility
Methods for Cancer Immunotherapy
2 Feb 23
The present invention encompasses methods of cancer immunotherapy, and particularly methods of allogeneic cellular immunotherapy, using particular lymphodepletion regimens in combination with particular populations of chimeric antigen receptor T cells expressing anti CD19 CAR PBCAR0191, anti CD20 CAR PBCAR20A or anti BCMA CAR PBCAR269A.
Bruce J. McCreedy, Jr., Derek Jantz, Aaron Martin, Daniel T. MacLeod
Filed: 3 Dec 20
Utility
CD20 Chimeric Antigen Receptors and Methods of Use for Immunotherapy
29 Dec 22
Provided herein are compositions and methods for the treatment of a disease, such as cancer, using a chimeric antigen receptor or genetically-modified cells comprising a chimeric antigen receptor having specificity for CD20.
Daniel T. MacLeod, Bruce J. McCreedy, JR., Aaron Martin
Filed: 30 Oct 20
Utility
Methods and Products for Producing Engineered Mammalian Cell Lines with Amplified Transgenes
20 Oct 22
Methods of inserting genes into defined locations in the chromosomal DNA of cultured mammalian cell lines which are subject to gene amplification are disclosed.
Derek Jantz, James Jefferson Smith, Michael G. Nicholson
Filed: 27 Jan 22
Utility
Compositions and Methods for Sequential Stacking of Nucleic Acid Sequences into a Genomic Locus
1 Sep 22
The present invention encompasses compositions and methods for the sequential stacking of donor nucleic acids into a single genomic locus within a cell to allow for the introduction of relatively long nucleic sequences.
Joann Hux, James Jefferson Smith
Filed: 24 Jul 20
Utility
Lymphodepletion Dosing Regimens for Cellular Immunotherapies
1 Sep 22
The present invention encompasses methods and compositions including genetically-modified cells expressing chimeric antigen receptors or exogenous T cell receptors, and pharmaceutical compositions thereof, for the treatment of cancer and other disorders and diseases.
Bruce J. McCreedy, Jr.
Filed: 20 Aug 20